WallStSmart

Biomerica Inc (BMRA)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 422197% more annual revenue ($20.63B vs $4.88M). GEHC leads profitability with a 10.1% profit margin vs -74.8%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

BMRA

Avoid

26

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -12.51

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BMRA.

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMRA2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

BMRA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.37M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-69.6%2/10

ROE of -69.6% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BMRA

The strongest argument for BMRA centers on Price/Book, Debt/Equity.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : BMRA

The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

BMRA profiles as a turnaround stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biomerica Inc

HEALTHCARE · MEDICAL DEVICES · USA

Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology company specializing in the development and manufacturing of cutting-edge diagnostic solutions across the medical and food sectors. With a strong focus on proprietary testing methods for managing metabolic diseases, gastrointestinal disorders, and food intolerances, Biomerica is committed to improving healthcare outcomes. The company actively engages in strategic research collaborations, positioning itself to address critical unmet medical needs and harness growth opportunities in the rapidly evolving diagnostics landscape. Leveraging technological advancements and a patient-centered approach, Biomerica is well-positioned to lead transformational changes in global healthcare diagnostics.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?